1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6DBBCFA747879588F852584B6001A324A
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/SearchNew?OpenForm&Query=(hr%20or%20human%20resource)%20and%20(field%20ItemCatalog%3DBMR)&SearchWV=1&ItemCatalog=BMR&SearchOrder=1&Start=71&Count=10
18
19OpenForm&Query=(hr%20or%20human%20resource)%20and%20(field%20ItemCatalog%3DBMR)&SearchWV=1&ItemCatalog=BMR&SearchOrder=1&Start=71&Count=10
203.227.3.146
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




Search Results

Results 71 - 77 of 77 Total Hits, Sorted by Relevance.

    |    

Health Outcomes Liaison Excellence: How the HOL Function Drives Value Across the Healthcare IndustryDirect access to this research is not included with your membership level.

Biopharmaceutical and medical device companies in the current outcomes-focused market depend increasingly upon Health Outcomes Liaison (HOL) staff to... (ID PSM-287)
Companies Profiled: Amgen, Becton Dickinson, Boehringer Ingelheim, Cubist, more ...

Managing Cross-Functional Teams for Pharmaceutical Product Commercialization ExcellenceDirect access to this research is not included with your membership level.

The most comprehensive resource allocation system and the best econometric model will still produce sub-optimal results if key managers and personnel... (ID HR-63)
Companies Profiled: 3M Pharmaceuticals, Sanofi-aventis, aaiPharma, Amgen, more ...

Real World Evidence: Understand Trends & Seize Opportunities in the Changing Landscape of RWE GenerationDirect access to this research is not included with your membership level.

Forward-looking pharmaceutical companies are taking rapid steps to boost their internal Real World Evidence (RWE) capabilities to better inform payers and their formulary and reimbursement decisions... (ID POP-294)
Companies Profiled: Abbott, Abbvie, Allergan, AstraZeneca, more ...

From Genes to Giants: Best Practices in Early-Stage Product CommercializationDirect access to this research is not included with your membership level.

Long and costly product development cycles make it essential today for pharmaceutical companies to allocate resources to the development of compounds with the greatest potential market value... (ID SM-162)
Companies Profiled: Abbott, Allergan, Bayer, Boehringer-Ingelheim, more ...

Finding and Keeping Top Investigators: Best Practices in Investigator Recruitment and RetentionDirect access to this research is not included with your membership level.

Effective clinical communications can not only add billions of dollars to a company's top-line growth, it can also have a critical impact on the bottom-line during development... (ID OP-85)
Companies Profiled: AAI Corporation, Sanofi-aventis, America's Doctor, AstraZeneca, more ...

Best Practices for Internal Communications Regarding Brands & Disease StateDirect access to this research is not included with your membership level.

When a promising new pharmaceutical product fails to meet expectations, poor brand communications may be a contributing cause... (ID POP-229)
Companies Profiled: Abbott Laboratories, Sanofi-aventis, Actelion, Boehringer Ingelheim, more ...

Raising Disease State Awareness: Best Practices in Internal Brand Messaging for New ProductsDirect access to this research is not included with your membership level.

Educating the marketplace about disease state is crucial to the success of a new pharmaceutical product— especially if the product treats a medical ... (ID OP-106)
Companies Profiled: Abbott, Novartis, Actelion, Novo Nordisk, more ...